Tolero Pharmaceuticals to Present Alvocidib Regimen Data at Upcoming Medical Conferences

SALT LAKE CITY--()--Tolero Pharmaceuticals, Inc., a late stage pharmaceutical company developing treatments for serious hematological diseases, today announced the upcoming scientific presentations of alvocidib at the Society of Hematologic Oncology SOHO 2015 Annual Meeting in Houston, Texas, taking place September 16 through 19, and the 2015 American Society of Hematology (ASH) Meeting on Hematology and Malignancies in Chicago, taking place September 17 through 19. The presentations mechanistically describe the validated clinical activity of alvocidib, a potent CDK9 inhibitor, within a time-sequential regimen in combination with chemotherapeutic agents in patients with acute myeloid leukemia (AML). Furthermore, the results presented provide clear rationale for alvocidib’s MCL-1-dependent mechanism of action and rationale for the impending randomized Phase II biomarker-driven clinical trial in patients with AML (clinicaltrials.gov - NCT02520011).

“Alvocidib Potentiates the Activity of Cytarabine and Mitoxantrone in a Time Sequential Regimen in AML through the Targeting of MCL-1”

Details of the poster presentations are as follows:

Medical Conference: SOHO 2015 Annual Meeting
Abstract: #15131
Poster: #222
Presenter: Clifford J. Whatcott, Ph.D.
Title: “The MCL-1 targeting effect of alvocidib potentiates the activity of cytarabine and mitoxantrone in a time-sequential regimen in AML”
Date: Wednesday, September 16, 2015; 6:00 p.m.-9:00 p.m. CDT
Location: Hilton-Americas Hotel, Grand Ballroom A-C on Level 4, Houston, Texas
 
Medical Conference: ASH Meeting on Hematology and Malignancies
Abstract: #78005
Poster: #23
Session Title: Leukemia – Acute Myeloid Leukemia
Presenter: Steven L. Warner, Ph.D.
Title: “Alvocidib Potentiates the Activity of Cytarabine and Mitoxantrone in a Time Sequential Regimen in AML through the Targeting of MCL-1”
Date: Friday, September 18, 2015; 6:40 p.m.-8:40 p.m. CDT
Location: Fairmont Chicago, Millennium Park, Imperial Ballroom, Chicago
 

About Alvocidib

Alvocidib is a potent small molecule inhibitor of cyclin-dependent kinase 9 (CDK9) in development as a combination therapy for frontline and relapsed/refractory AML. CDK9 is a protein critical to the regulation of gene expression including the MCL-1 gene and other important genes involved in cancer. Given the key role CDK9 de-regulation plays in expression of cancer-associated genes related to cell division and proliferation, CDK9 is an attractive target for the treatment of various cancers.

About Tolero

Tolero Pharmaceuticals is a clinical stage biopharmaceutical company developing treatments to improve and extend the lives of patients with serious oncological and hematological diseases. Our diverse pipeline targets important biological drivers of blood disorders to treat leukemias and anemia as well as important targets of drug resistance and transcriptional control.

Contacts

Tolero Pharmaceuticals, Inc.
Joe Nilson, 801-285-6003
bizdev@toleropharma.com